Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Most tumors grow in immunocompetent hosts despite expressing NKG2D ligands (NKG2DLs) such as the MHC class I chain-related genes A and B (MICA/B). However, their participation in tumor cell evasion is still not completely understood. Here we demonstrate that several human melanomas (cell lines and freshly isolated metastases) do not express MICA on the cell surface but have intracellular deposits of this NKG2DL. Susceptibility to NK cell-mediated cytotoxicity correlated with the ratio of NKG2DLs to HLA class I molecules but not with the amounts of MICA on the cell surface of tumor cells. Transfection-mediated overexpression of MICA restored cell surface expression and resulted in an increased in vitro cytotoxicity and IFN-γ secretion by human NK cells. In xenografted nude mice, these melanomas exhibited a delayed growth and extensive in vivo apoptosis. Retardation of tumor growth was due to NK cell-mediated antitumor activity against MICA-transfected tumors, given that this effect was not observed in NK cell-depleted mice. Also, mouse NK cells killed MICA-overexpressing melanomas in vitro. A mechanistic analysis revealed the retention of MICA in the endoplasmic reticulum, an effect that was associated with accumulation of endoH-sensitive (immature) forms of MICA, retrograde transport to the cytoplasm, and degradation by the proteasome. Our study identifies a novel strategy developed by melanoma cells to evade NK cell-mediated immune surveillance based on the intracellular sequestration of immature forms of MICA in the endoplasmic reticulum. Furthermore, this tumor immune escape strategy can be overcome by gene therapy approaches aimed at overexpressing MICA on tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Cerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function
Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C. T., Spies, T., & Bukowski, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00168-6 · Cited by 409
Cited by
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
NKG2D and Its Ligands: “One for All, All for One”
Zingoni, A., Molfetta, R., Fionda, C., Soriani, A., Paolini, R., Cippitelli, M., Cerboni, C., & Santoni, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00476 · Cited by 254
López-Cobo, S., Pieper, N., Campos-Silva, C., García-Cuesta, E. M., Reyburn, H. T., Paschen, A., & Valés-Gómez, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1392426 · Cited by 71
“NKG2D and its ligands constitute the best characterised system involved in NK surveillance of cancer(38) and melanoma cells are known to express various NKG2D-L affecting NK cell recognition.(20,39,40) Here, we demonstrate that exposure to the BRAFi, vemurafenib, modulates the surface expression of NKG2D-L, CD155 and…”
BackgroundEGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells
Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
Torres, N., Regge, M. V., Secchiari, F., Friedrich, A. D., Spallanzani, R. G., Raffo Iraolagoitia, X. L., Núñez, S. Y., Sierra, J. M., Ziblat, A., Santilli, M. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000233 · Cited by 29
Self-citation
Metadata
- Authors
- Fuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A., & Zwirner, N. W.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-01
- Volume
- 180
- Issue
- 7
- Pages
- 4606-4614
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1614344254
- Cited by
- 105
- References
- 6
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.